Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling

Molecular Systems Biology

Volumn 10, Issue 3, 2014, Pages

  Agren, Rasmus ^a   Mardinoglu, Adil ^a   Asplund, Anna ^b   Kampf, Caroline ^b   Uhlen, Mathias ^c   Nielsen, Jens ^a,b  

^a CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

antimetabolites; genome scale metabolic models; hepatocellular carcinoma; personalized medicine; proteome

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; ANTINEOPLASTIC AGENT;

ALGORITHM; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL TYPE; CLINICAL ARTICLE; COMPUTER MODEL; DRUG IDENTIFICATION; FEMALE; GENOME SCALE METABOLIC MODEL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIPID OXIDATION; LIVER CELL; LIVER CELL CARCINOMA; MALE; MITOSIS; MOLECULAR MODEL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; BIOLOGICAL MODEL; COMPUTER SIMULATION; DRUG DEVELOPMENT; HUMAN GENOME; LIVER TUMOR; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; COMPUTER SIMULATION; DRUG DISCOVERY; GENOME, HUMAN; HUMANS; INDIVIDUALIZED MEDICINE; LIVER NEOPLASMS; MODELS, BIOLOGICAL; PROTEOMICS;

EID: 84898663879     PISSN: None     EISSN: 17444292     Source Type: Journal    
DOI: 10.1002/msb.145122     Document Type: Article

References (50)

1. Agren R, Bordel S, Mardinoglu A, Pornputtapong N, Nookaew I, Nielsen J, (2012) Reconstruction of genome-scale active metabolic networks for 69 human cell types and 16 cancer types using INIT. PLoS Comput Biol 8: e1002518
2. Agren R, Liu L, Shoaie S, Vongsangnak W, Nookaew I, Nielsen J, (2013) The RAVEN Toolbox and its use for generating a genome-scale metabolic model for Penicillium chrysogenum. PLoS Comput Biol 9: e1002980
3. Borena W, Strohmaier S, Lukanova A, Bjorge T, Lindkvist B, Hallmans G, Edlinger M, Stocks T, Nagel G, Manjer J, Engeland A, Selmer R, Haggstrom C, Tretli S, Concin H, Jonsson H, Stattin P, Ulmer H, (2012) Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. Int J Cancer 131: 193-200
4. Bruix J, Sherman M, (2011) Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022
5. Carracedo A, Cantley LC, Pandolfi PP, (2013) Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer 13: 227-232
6. Chen L, Zeng X, Wang J, Briggs SS, O'Neill E, Li J, Leek R, Kerr DJ, Harris AL, Cai S, (2010) Roles of tetrahydrobiopterin in promoting tumor angiogenesis. Am J Pathol 177: 2671-2680
7. Chen R, Mias GI, Li-Pook-Than J, Jiang LH, Lam HYK, Chen R, Miriami E, Karczewski KJ, Hariharan M, Dewey FE, Cheng Y, Clark MJ, Im H, Habegger L, Balasubramanian S, O'Huallachain M, Dudley JT, Hillenmeyer S, Haraksingh R, Sharon D, et al, (2012) Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 148: 1293-1307
8. Cuthbert JA, Lipsky PE, (1997) Regulation of proliferation and Ras localization in transformed cells by products of mevalonate metabolism. Cancer Res 57: 3498-3505 (Pubitemid 27355498)
9. Duarte NC, Becker SA, Jamshidi N, Thiele I, Mo ML, Vo TD, Srivas R, Palsson BO, (2007) Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc Natl Acad Sci USA 104: 1777-1782 (Pubitemid 46239855)
10. Finn RS, (2010) Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now? Clin Cancer Res 16: 390-397
11. Folger O, Jerby L, Frezza C, Gottlieb E, Ruppin E, Shlomi T, (2011) Predicting selective drug targets in cancer through metabolic networks. Mol Syst Biol 7: 501
12. Frezza C, Zheng L, Folger O, Rajagopalan KN, MacKenzie ED, Jerby L, Micaroni M, Chaneton B, Adam J, Hedley A, Kalna G, Tomlinson IPM, Pollard PJ, Watson DG, Deberardinis RJ, Shlomi T, Ruppin E, Gottlieb E, (2011) Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature 477: 225-228
13. Garg D, Henrich S, Salo-Ahen OM, Myllykallio H, Costi MP, Wade RC, (2010) Novel approaches for targeting thymidylate synthase to overcome the resistance and toxicity of anticancer drugs. J Med Chem 53: 6539-6549
14. Giannelli G, Napoli N, Antonaci S, (2007) Tyrosine kinase inhibitors: a potential approach to the treatment of hepatocellular carcinoma. Curr Pharm Des 13: 3301-3304 (Pubitemid 350201685)
15. Hebar A, Valent P, Selzer E, (2013) The impact of molecular targets in cancer drug development: major hurdles and future strategies. Expert Rev Clin Pharmacol 6: 23-34
16. Hood L, Balling R, Auffray C, (2012) Revolutionizing medicine in the 21st century through systems approaches. Biotechnol J 7: 992-1001
17. Hood L, Friend SH, (2011) Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol 8: 184-187
18. Huang DW, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57
19. Ishizuka M, Abe F, Sano Y, Takahashi K, Inoue K, Nakajima M, Kohda T, Komatsu N, Ogura S, Tanaka T, (2011) Novel development of 5-aminolevulinic acid (ALA) in cancer diagnoses and therapy. Int Immunopharmacol 11: 358-365
20. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90
21. Kampf C, Andersson AC, Wester K, Björling E, Uhlén M, Pontén F, (2004) Antibody-based tissue profiling as a tool for clinical proteomics. Clin Proteomics 1: 285-299 (Pubitemid 41271299)
22. Kampf C, Olsson I, Ryberg U, Sjöstedt E, Pontén F, (2012) Production of tissue microarrays, immunohistochemistry staining and digitalization within the human protein atlas. J Vis Exp 63: e3620
23. Khasawneh J, Schulz MD, Walch A, Rozman J, de Angelis MH, Klingenspor M, Buck A, Schwaiger M, Saur D, Schmid RM, Kloppel G, Sipos B, Greten FR, Arkan MC, (2009) Inflammation and mitochondrial fatty acid beta-oxidation link obesity to early tumor promotion. Proc Natl Acad Sci USA 106: 3354-3359
24. Kim HU, Kim SY, Jeong H, Kim TY, Kim JJ, Choy HE, Yi KY, Rhee JH, Lee SY, (2011) Integrative genome-scale metabolic analysis of Vibrio vulnificus for drug targeting and discovery. Mol Syst Biol 7: 460
25. Lazar MA, Birnbaum MJ, (2012) De-meaning of metabolism. Science 336: 1651-1652
26. Leong TY, Leong AS, (2005) Epidemiology and carcinogenesis of hepatocellular carcinoma. HPB 7: 5-15 (Pubitemid 40425752)
27. Liu Y, (2006) Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis 9: 230-234 (Pubitemid 44317255)
28. Lonardo A, Loria P, (2012) Potential for statins in the chemoprevention and management of hepatocellular carcinoma. J Gastroenterol Hepatol 27: 1654-1664
29. Mardinoglu A, Agren R, Kampf C, Asplund A, Nookaew I, Jacobson P, Walley AJ, Froguel P, Carlsson LM, Uhlen M, Nielsen J, (2013a) Integration of clinical data with a genome-scale metabolic model of the human adipocyte. Mol Syst Biol 9: 649
30. Mardinoglu A, Agren R, Kampf C, Asplund A, Uhlen M, Nielsen J, (2014) Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease. Nat Commun 5: 3083
31. Mardinoglu A, Gatto F, Nielsen J, (2013b) Genome-scale modeling of human metabolism-a systems biology approach. Biotechnol J 8: 985-996
32. Mardinoglu A, Nielsen J, (2012) Systems medicine and metabolic modelling. J Intern Med 271: 142-154
33. Munoz-Pinedo C, El Mjiyad N, Ricci JE, (2012) Cancer metabolism: current perspectives and future directions. Cell Death Dis 3: e248
34. Pacilli A, Calienni M, Margarucci S, D'Apolito M, Petillo O, Rocchi L, Pasquinelli G, Nicolai R, Koverech A, Calvani M, Peluso G, Montanaro L, (2013) Carnitine-acyltransferase system inhibition, cancer cell death, and prevention of myc-induced lymphomagenesis. J Natl Cancer Inst 105: 489-498
35. Padhya KT, Marrero JA, Singal AG, (2013) Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroen 29: 285-292
36. Pekala J, Patkowska-Sokola B, Bodkowski R, Jamroz D, Nowakowski P, Lochynski S, Librowski T, (2011) L-carnitine-metabolic functions and meaning in humans life. Curr Drug Metab 12: 667-678
37. Pike LS, Smift AL, Croteau NJ, Ferrick DA, Wu M, (2011) Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim Biophys Acta 1807: 726-734
38. Rebouche CJ, (1991) Quantitative estimation of absorption and degradation of a carnitine supplement by human adults. Metabolism 40: 1305-1310
39. Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, Korchin B, Kaluarachchi K, Bornmann W, Duvvuri S, Taegtmeyer H, Andreeff M, (2010) Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest 120: 142-156
40. Sanyal AJ, Yoon SK, Lencioni R, (2010) The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 15 (Suppl. 4): 14-22
41. Silverio R, Laviano A, Rossi Fanelli F, Seelaender M, (2011) L-carnitine and cancer cachexia: clinical and experimental aspects. J Cachexia Sarcopenia Muscle 2: 37-44
42. Thiele I, Swainston N, Fleming RM, Hoppe A, Sahoo S, Aurich MK, Haraldsdottir H, Mo ML, Rolfsson O, Stobbe MD, Thorleifsson SG, Agren R, Bolling C, Bordel S, Chavali AK, Dobson P, Dunn WB, Endler L, Hala D, Hucka M, et al, (2013) A community-driven global reconstruction of human metabolism. Nat Biotechnol 31: 419-425
43. Toshima T, Shirabe K, Matsumoto Y, Yoshiya S, Ikegami T, Yoshizumi T, Soejima Y, Ikeda T, Maehara Y, (2013) Autophagy enhances hepatocellular carcinoma progression by activation of mitochondrial beta-oxidation. J Gastroenterol, doi: 10.1007/s00535-013-0835-9
44. Uhlen M, Bjorling E, Agaton C, Szigyarto CA, Amini B, Andersen E, Andersson AC, Angelidou P, Asplund A, Asplund C, Berglund L, Bergstrom K, Brumer H, Cerjan D, Ekstrom M, Elobeid A, Eriksson C, Fagerberg L, Falk R, Fall J, et al, (2005) A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics 4: 1920-1932 (Pubitemid 41830186)
45. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, Zwahlen M, Kampf C, Wester K, Hober S, Wernerus H, Bjorling L, Ponten F, (2010) Towards a knowledge-based human protein atlas. Nat Biotechnol 28: 1248-1250
46. Vander Heiden MG, (2011) Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 10: 671-684
47. Väremo L, Nookaew I, Nielsen J, (2013) Novel insights into obesity and diabetes through genome-scale metabolic model. Front Physiol 4: 1
48. Wu PC, Lai CL, Liddel RH, (1984) Quantitative morphology of mitochondria in hepatocellular carcinoma and chronic liver disease. Arch Pathol Lab Med 108: 914-916 (Pubitemid 15202909)
49. Ye GZ, Zhu B, Yao ZZ, Yin PY, Lu X, Kong HW, Fan F, Jiao BH, Xu GW, (2012) Analysis of urinary metabolic signatures of early hepatocellular carcinoma recurrence after surgical removal using gas chromatography-mass spectrometry. J Proteome Res 11: 4361-4372
50. Zaugg K, Yao Y, Reilly PT, Kannan K, Kiarash R, Mason J, Huang P, Sawyer SK, Fuerth B, Faubert B, Kalliomaki T, Elia A, Luo X, Nadeem V, Bungard D, Yalavarthi S, Growney JD, Wakeham A, Moolani Y, Silvester J, et al, (2011) Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev 25: 1041-1051